Evaluation of Safety and Efficacy of Morpheus8 Applicator for the Treatment of Focal Hyperhidrosis of the Axillae Using Radio Frequency

Status unconfirmed · Not applicable · Has a placebo group

Conditions studied: Hyperhidrosis Primary Focal Axilla

In brief

The InMode radio frequency Pro System with the Morpheus8 Applicator is a computerized system generating radio frequency energy, based on the underlying technology of Fractional RF. The Morpheus8 Applicator and 24 pin tip is used for the treatment of primary hyperhidrosis of the axillae

Key facts

Study ID: NCT05860972
Run by: InMode MD Ltd.
People needed: 70
Starts: 2023-03-09
Expected to finish: 2026-04-01
Last updated by the study team: 2024-01-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

Subject is 18 years of age or older at the time of consent.
Subject reports a quality-of-life rating of 3 or 4 on the Hyperhidrosis Disease Severity Scale (HDSS).
Subject has primary focal axillary hyperhidrosis evidenced by at least 6 months of visible, detectable, focal, exaggerated sweating without any apparent explanation and at least two of the following:
Bilateral and relatively symmetric
Impairs daily activities
Frequency of at least one episode per week
Age of onset less than 25 years old
Positive family history
Cessation of focal sweating during sleep
Subject is willing and able to comply with protocol requirements and all study visits
Willing to have de-identified images of the treated areas taken for possible use in publications and presentations.
Subject understands the study and has provided written informed consent

You may not qualify if…

Subject has secondary hyperhidrosis due to medications, infections, malignancy or endocrinopathy.
Poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction and hormonal virilization.
Severe concurrent conditions such as cardiac disorders epilepsy, uncontrolled hypertension, and liver or kidney diseases.
Any active skin condition in the treatment area, such as sores, psoriasis, eczema and rash.
Swollen axillary lymph nodes.
History of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin.
Impaired immune system due to immunosuppressive diseases such as AIDS and HIV, or use of immunosuppressive medications.
History of bleeding coagulopathies or use of anticoagulants in the last 10 days.
Prior endoscopic thoracic sympathectomy, liposuction or other surgery for hyperhidrosis in the treated area. Injection of botulinum toxin in the treated area within one year
Use of Isotretinoin (Accutane®) within 6 months prior to study
Oral anticholinergic medication use (e.g., Robinul) or cholinomimetic medication use within the last 4 weeks or planned use during the study's follow up phase.
Currently participating in or recently participated in another clinical trial (within the last 30 days).
History of or current neurologic deficit in the treatment limb.
Known resistance to or history of difficulty with local anesthesia (lidocaine with epinephrine).
Current or history of cancer, including skin cancer, or premalignant moles.
Injury in the treatment area or any other condition that, in the opinion of the investigator, might make treatment unsafe.
Subject has a pacemaker, defibrillator or other electronic implant anywhere in the body.
Permanent implant in the treated area such as metal plates, screws and metal piercing or silicon.
Females who are pregnant or nursing
Female subjects of childbearing potential not willing to use an acceptable form of contraception for the duration of the study.

Where it is running

Southeastern Dermatology — Knoxville, Tennessee, United States (enrolling)
Dallas Plastic Surgery Institute — Dallas, Texas, United States (enrolling)
Skinfluence — New York, New York, United States
RAMBAM Medical Center — Haifa, Israel

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.